GSK plc GSK
Set alert
As of Nov 3, 1:34 PM ET
- YTD
- -0.22%
- 1 year
- +5.57%
- Open
- 49.41
- Prev close
- 49.13
- Mkt cap
- 98.06B
- Vol
- 1.59M
- Avg vol
- 4.05M
- EPS
- 2.87
- P/E
- 17.05
- Div yield
- 3.64%
More statistics
- Low
- 48.85
- High
- 49.57
- Forward P/E
- 9.91
- Beta
- 0.28
- Short ratio
- 2.86
- Inst. own
- 17.46%
- Dividend
- 1.82
- Ex-div date
- Aug 13, 2026
- Earnings
- Feb 3, 2027
- 50-d avg
- 49.43
- 200-d avg
- 52.34
- 1y target
- 59.12
5D chart
Events in this range
- Oct 28, 2026Earnings: 1.47; estimate 1.33; surprise 10.53%
- Oct 29, 2026Downgrade: Jefferies · Buy → Hold
Signals (81)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 9:30 AM | 1 day ago |
| RSI: Oversold | Nov 2, 9:30 AM | 1 day ago |
| SMA: Bearish | Oct 30, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 30, 1:50 PM | 4 days ago |
| SMA: Bullish | Oct 30, 1:30 PM | 4 days ago |
| SMA: Bearish | Oct 30, 1:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 30, 1:25 PM | 4 days ago |
| RSI: Overbought | Oct 30, 12:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 30, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 30, 12:10 PM | 4 days ago |
| SMA: Bullish | Oct 30, 12:05 PM | 4 days ago |
| SMA: Bearish | Oct 30, 11:35 AM | 4 days ago |
| SMA: Bearish | Oct 30, 11:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 30, 10:15 AM | 4 days ago |
| SMA: Bearish | Oct 30, 10:05 AM | 4 days ago |
| RSI: Overbought | Oct 29, 3:55 PM | 4 days ago |
| RSI: Overbought | Oct 29, 3:45 PM | 4 days ago |
| RSI: Overbought | Oct 29, 3:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 3:05 PM | 4 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 4 days ago |
Newest 20 of 81.
News
4 days ago seekingalpha.com
GSK: The Gas Pedal Is Still Down, But Bumps Ahead
Despite the Q3 disappointments, I maintain my Buy rating, as strong Specialty Medicines growth and improving pipeline momentum continue to support GSK's long-term ambitions. Specialty Medicines…
-
4 days ago benzinga.com
Jefferies Downgrades GSK to Hold, Lowers Price Target to $55.9
Jefferies analyst Michael Leuchten downgrades GSK (NYSE:GSK) from Buy to Hold and lowers the price target from $67.4 to $55.9.
5 days ago zacks.com
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?
GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.
5 days ago seekingalpha.com
GSK plc (GSK) Q3 2026 Earnings Call Transcript
GSK plc ( GSK ) Q3 2026 Earnings Call October 28, 2026 8:00 AM EDT Company Participants Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations Luke Miels - CEO & Director…
6 days ago marketbeat.com
What GSK (GSK) Said on Its Q3 Earnings Call
GSK NYSE: GSK reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, supported by specialty medicines, new product launches and oncology growth. Core operating profit…
6 days ago zacks.com
GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales
GSK's Q3 earnings beat estimates as HIV, oncology and respiratory medicines drive revenue growth, while declining vaccine sales weigh on shares.
6 days ago benzinga.com
GSK's Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 Beat
GSK Plc (NYSE:GSK) reported third-quarter adjusted earnings of $1.47 per share (54.6 pence), beating the analyst consensus estimate of $1.40.
6 days ago benzinga.com
GSK’s Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 Beat
GSK beat Q3 analyst consensus with $1.47 adjusted EPS and $11.95 billion revenue, as specialty drugs offset vaccine drops. 2026 outlook reaffirmed.
6 days ago seekingalpha.com
GSK: Why I'm Still Bullish After Strong Q3 Results
GSK plc delivered strong results today. In the third quarter, revenue and non-GAAP EPS grew 5.7% and 8.2% quarter-on-quarter, respectively. Cabenuva, GSK's long-acting HIV treatment, generated $641…
-
6 days ago benzinga.com
UPDATE: GSK Q3 Adj. EPS $1.47 Beats $1.40 Estimate, Sales $11.948B Beat $11.800B Estimate
GSK (NYSE:GSK) reported quarterly earnings of $1.47 per share which beat the analyst consensus estimate of $1.40 by 5 percent. This is a 0.68 percent decrease over earnings of $1.48 per share from…
6 days ago benzinga.com
GSK Q3 2026 Earnings Call Transcript
GSK (NYSE:GSK) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
6 days ago zacks.com
GSK (GSK) Q3 Earnings and Revenues Beat Estimates
GSK (GSK) came out with quarterly earnings of $1.47 per share, beating the Zacks Consensus Estimate of $1.4 per share. This compares to earnings of $1.48 per share a year ago.
6 days ago wsj.com
GSK Sales Get Boost From Specialty Medicines
The U.K. drugmaker's strength in the segment allowed it to offset a declining vaccines revenue and a flat performance in general medicines.
-
6 days ago benzinga.com
GSK Affirms FY2026 Adj EPS Guidance of $4.90-$5.00 vs $4.78 Est; Affirms FY2026 Sales Guidance of $44.754B vs $45.150B Est
GSK (NYSE:GSK) affirms FY2026 Adj EPS guidance from $4.90-$5.00 to $4.90-$5.00 vs $4.78 analyst estimate. Affirms FY2026 sales outlook from $44.754 billion to $44.754 billion vs $45.150 billion…
-
6 days ago benzinga.com
GSK Q3 Adj. EPS $1.47 Beats $1.40 Estimate, Sales $11.948B Beat $11.800B Estimate
GSK (NYSE:GSK) reported quarterly earnings of $1.47 per share which beat the analyst consensus estimate of $1.40 by 5 percent. This is a 0.68 percent decrease over earnings of $1.48 per share from…
6 days ago reuters.com
GSK beats third-quarter profit estimates, keeps annual targets
GSK beat third-quarter sales and profit expectations on Wednesday, helped by demand for specialty medicines, suggesting CEO Luke Miels' efforts to accelerate growth and prepare the drugmaker for
6 days ago seekingalpha.com
GSK plc (GSK) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript
GSK plc (GSK) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript
6 days ago benzinga.com
Microsoft, Alphabet On Deck Wednesday As AI Spending, Cloud Growth Face Test
Microsoft and Alphabet headline Wednesday’s reports, with investors weighing whether AI infrastructure spending is translating into durable cloud and advertising growth. GE Vernova, Amphenol, Banco…
1 week ago marketbeat.com
GSK Showcases Strong Oncology Pipeline Data at ESMO Investor Update
GSK NYSE: GSK highlighted clinical data across its oncology pipeline at the European Society for Medical Oncology meeting, including updates for its B7-H3 antibody-drug conjugate ris-rez, B7-H4 ADC…
-
1 week ago benzinga.com
Wave Life Sciences Anticipates $12M Milestone Payment From GSK In Q4
Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results…
1 week ago reuters.com
GSK to nearly double cancer drugs in trials, WSJ reports
GSK expects to nearly double the number of cancer medicines it is testing in clinical trials next year, the Wall Street Journal reported on Tuesday, citing an interview with a scientist
1 week ago wsj.com
GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree
EXCLUSIVE: The U.K. drugmaker currently has five approved cancer medicines and a clinical-stage portfolio of about 15 assets.
-
1 week ago benzinga.com
GSK’s Ris-Rez Meets Primary Endpoint In Phase III ARTEMIS-011 Trial, Reducing Risk Of Progression Or Death By 67%, Improving Median Progression-Free Survival To 5.5 Months Vs. 1.4 Months With Chemotherapy In Relapsed Or Refractory Osteosarcoma
Patients receiving Ris-Rez remained progression-free for a median of 5.5 months versus 1.4 months with comparatorSecond positive phase III trial in China adds to growing body of late-stage evidence…
-
1 week ago benzinga.com
Reported Saturday, GSK’s Jemperli Monotherapy Shows Generally Consistent Safety, With Serious Adverse Reactions In 20% And Discontinuations In 3%, Alongside 76% Complete Response In Phase II AZUR-1 MSI-H/dMMR Rectal Cancer Trial
Patients had no evidence of cancer following treatment with Jemperli alone, as confirmed by endoscopy, radiology and/or pathologyNo disease recurrences reported among responders after median…
1 week ago 247wallst.com
Can Specialty Meds Offset GSK's $2.2B Legal Charges and Sizzling R&D Setbacks on Oct. 28?
GSK (NYSE:GSK | GSK Price Prediction) reports third-quarter results on October 28. A $2.
1 week ago zacks.com
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 week ago benzinga.com
GSK Wins FDA Approval For Chronic Hepatitis B Drug
FDA clears GSK Hibsago for chronic hepatitis B in adults, delivering strong functional cure rates and suppressing viral replication targets.
1 week ago proactiveinvestors.com
GSK hepatitis B drug approval supports £2.2bn sales forecast, Jefferies says
Jefferies has reiterated its 'buy' rating on GSK PLC (LSE:GSK, NYSE:GSK), the pharmaceutical company, with a 2,500p price target after US regulators approved its hepatitis B treatment, Hibsago. The…
1 week ago businesswire.com
Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB)
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B…
1 week ago reuters.com
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
2 weeks ago zacks.com
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth
GSK's newer drugs, expanding indications and promising pipeline could drive long-term growth, with sales expected to exceed 40 billion pounds by 2031.
2 weeks ago benzinga.com
FDA Clears GSK Drug That Could Change How Certain Rectal Cancers Are Treated
FDA approves GSK's Jemperli as first immunotherapy for dMMR/MSI-H rectal cancer, offering a surgery-free alternative.
2 weeks ago benzinga.com
Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push
Shah Capital sells 2.87M Novavax (NVAX) shares for $32.6M, ends activist campaign, and shifts to a family office structure.
3 weeks ago benzinga.com
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Analysts review high-yield healthcare stocks CVS, Medtronic and GSK, offering dividend yields of 3.02%-3.86% and varied ratings.
1 month ago benzinga.com
Why Is GSK Stock Gaining Monday?
GSK shares jump over 4% on strong survival data for SCLC drug Ris-Rez and a 94% response rate for Jideytro in NSCLC.
-
1 month ago benzinga.com
GSK's Jideytro Achieves 94% Objective Response Rate At 15.2 Months Follow-Up In TKI-Naïve ROS1-Positive NSCLC, ARROS-1 Trial Shows
94% objective response rate at 15.2 months follow-up90% of patients were progression free at 12 months, with median PFS rate still to be reached70% of patients with measurable brain metastases…
1 month ago benzinga.com
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Analyst ratings and news for high-yield healthcare stocks Medtronic (3.06%), Smith & Nephew (2.74%) and GSK (3.65%).
1 month ago benzinga.com
8 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
2 months ago benzinga.com
Sensodyne Maker Haleon Leverages Eye-Level Shelf Placement To Outpace Rivals-Report
Haleon gains US market share at Walmart and Target by securing eye-level shelf placement with aggressive promotional strategies.
2 months ago benzinga.com
Why Is HUTCHMED Stock Soaring Thursday?
HUTCHMED stock jumps on a $1.3B GSK deal for its cancer drug HMPL-A830. Learn the financial terms and key global rights split.
2 months ago benzinga.com
GSK Says Immune Response from mRNA Flu Shot Surpasses Licensed Competitors
GSK moves its dual-target mRNA seasonal flu vaccine to Phase 3 trials following strong Phase 2 data and FDA Fast Track status.
2 months ago benzinga.com
Measles Kills 2 in Pennsylvania: What Do Prediction Markets Say About the Disease?
Two unvaccinated Pennsylvania residents died of measles, the state’s first deaths in 35 years, as traders see 89% odds of 4,000 U.S. cases.
2 months ago benzinga.com
Dr. Oz Says The MMR Vaccine Is Not 'Lethal' as Trump Administration Faces Questions Over Vaccine Policy
Oz says the MMR vaccine is “not a lethal vaccine” after Trump warned the combined shot could be “quite lethal” amid vaccine policy scrutiny.
2 months ago benzinga.com
9 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
2 months ago benzinga.com
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During market turbulence, investors turn to dividend-yielding stocks. Benzinga provides analyst ratings for high-yield stocks in health care.
2 months ago benzinga.com
Trump Cuts Core Childhood Vaccine Recommendations to 11, Bill Cassidy Says 'This Executive Order Is Wrong' (UPDATED)
President Donald Trump signed an order Monday limiting core childhood vaccine recommendations to 11 vaccines.
-
2 months ago benzinga.com
Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All Children
https://youtu.be/H_RititNE8U
2 months ago benzinga.com
Trump Administration Reportedly Weighs Executive Order on Autism and Vaccines Days After RFK Jr. Hinted At 'Certain Interventions'
The Trump administration is reportedly considering an executive order on vaccines and autism as early as next week.
-
3 months ago benzinga.com
GSK Announces Cabenuva Demonstrates Superiority To Daily Oral Therapy In Adolescents Living With HIV, As Viiv Healthcare Highlights New Long-Acting Injectable Data At AIDS 2026
https://www.gsk.com/en-gb/media/press-releases/cabenuva-demonstrates-superiority-to-daily-oral-therapy-in-adolescents-living-with-hiv-as-viiv-healthcare-highlights-new-long-acting-injectable-data-at-a…
3 months ago benzinga.com
GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals
GSK beats Q2 revenue and earnings estimates, launches a $2.52B cost-savings program, and updates its 2026 guidance.